Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



It's Time to Buy Amgen Stock. Here's Why

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

It might not be obvious to the casual observer, but right now, today, Amgen (NASDAQ: AMGN  ) stock offers one of the best values available in biotech. Why?

Three reasons.

1. Amgen is cheap
When you stack up Amgen against a couple of its bigger rivals -- Johnson & Johnson (NYSE: JNJ  ) and Novartis (NYSE: NVS  ) , it's clear that Amgen stock is the best bargain of the three. Its 16.5 price-to-earnings ratio is 10% cheaper than Novartis's 18.3, and offers a near-28% discount to the 23 P/E at Johnson & Johnson.

Amgen also offers a cheaper "forward" P/E ratio -- just 11.8 -- and costs a mere fraction of the valuation on its rivals when measured under the rubric of price-to-free cash flow. Costing a relative pittance of just 18 times free cash, Amgen's valuation is cheaper-by-half than the P/FCF ratios at either Novartis or J&J.

2. Amgen has the best record around
Over the past five years, Amgen has grown its annual profits more than twice as fast as its closest rival. Amgen's notched a 15% annualized earnings growth to Novartis' 6.8%, and blown Johnson & Johnson's anemic 1.2% growth rate completely out of the water.

And if Amgen stock looks great in the rearview mirror, it looks nearly as good when viewed through the windshield. Going forward, Amgen promises to maintain its lead. Analysts on average see the stock outgrowing J&J by nearly half, and eclipsing Novartis's growth rate by an even larger margin.

3. Amgen pays you best
Perhaps most important to investors, though, is the fact that out of the three biotech stocks discussed above, Amgen is the firm generating the most cash from its business, giving you the biggest free cash flow bang for your investing buck.

Measured by dividing a firm's market capitalization (the price you pay for Amgen stock) into its free cash flow (the money your investment generates for you), Amgen offers investors quite simply the best "free cash flow yield" of the three firms named. Put even more simply, for every $1 you invest in a share of Amgen stock today, you can expect the firm to generate 6.8 cents worth of real, cash profits on your investment. What's more, Amgen has outperformed its rivals in this regard pretty consistently over time.

AMGN Free Cash Flow Yield Chart

AMGN Free Cash Flow Yield data by YCharts.

Amgen may ultimately use this cash to pay you bigger dividends (its current yield of 1.9% does, after all, lag both its rivals'). Or Amgen could use its cash to buy back shares (increasing the size of your stake in the company for every share it takes off the table), or to reinvest in its business and maintain its stellar pace of growth. Any way you look at it, though, Amgen's ability to generate cash offers investors a great reason to invest.

And that, Fools, is the reason I think now's a great time to buy Amgen stock.

Read/Post Comments (1) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 07, 2013, at 4:58 PM, MoreSaneVision wrote:

    Equating J&J and Novartis to a biotechnology company is like comparing Google to Time Warner and News Corp.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2478409, ~/Articles/ArticleHandler.aspx, 9/30/2016 8:02:47 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,308.15 164.70 0.91%
S&P 500 2,168.27 17.14 0.80%
NASD 5,312.00 42.85 0.81%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/30/2016 4:00 PM
AMGN $166.81 Up +1.36 +0.82%
Amgen CAPS Rating: ****
JNJ $118.13 Up +0.86 +0.73%
Johnson and Johnso… CAPS Rating: *****
NVS $78.96 Down -0.29 -0.37%
Novartis CAPS Rating: ****